Meiji Seika Of Japan Launches Larger Dose Of Depromel Antidepressant
This article was originally published in PharmAsia News
Japan's Meiji Seika Kaisha launched a larger-dose version of its Depromel (fluvoxamine maleate) antidepressant aimed at a greater share of the Japanese market. The newly marketed 75mg version allows patients to get the treatment by taking fewer pills, a convenience Meiji Seika plans to leverage. The company already has been marketing 50mg and 25mg versions of the drug. The drug, in all sizes, is marketed by Astellas Pharma under the brand name Luvox. (Click here for more - a subscription may be required
You may also be interested in...
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.
GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs
Rules covering OTC medical devices, herbals and online activities have been added for the first time to the Irish Pharmaceutical Healthcare Association's Self-Care Advertising Code.